Pantheon Secures $2.5M to Launch Development of Bioengineered Corneal Implant

Pantheon Vision has secured $2.5 million in seed financing from KeraLink International (KLI), a Baltimore-based non-profit organization dedicated to eliminating corneal blindness, with a specific focus on low- and middle-income countries.

This funding will launch the development bioengineered corneal implant.

"We are thrilled to have KeraLink provide our initial funding to establish Pantheon Vision as a company dedicated to bringing groundbreaking ophthalmic innovations to patients worldwide,” said John Sheets, PhD, Chief Executive Officer of Pantheon Vision. “This funding enables us to advance our program to eradicate corneal blindness and restore vision.”

Pantheon Vision's objective is to enhance global eye care standards and decrease dependence on donated corneal tissue, a scarcity in many low- and middle-income nations. The company will collaborate with the FDA in the near future to steer global product development plans.

Heading Pantheon Vision is Dr. John Sheets, a seasoned figure in the ophthalmic industry, having previously held leadership positions at companies like Hoya and Elisar, and research and development roles at Alcon, Bausch + Lomb, and Johnson & Johnson. Dr. Sheets also served as the head of the Office of Device Evaluation at the FDA.